Speciality Medicines IPO Details
| IPO Open Date | March 20, 2026 |
| IPO Close Date | March 24, 2026 |
| Face Value | ā¹10 Per Equity Share |
| IPO Price Band | ā¹117 to ā¹124 Per Share |
| Issue Size | Approx ā¹29.14 Crores |
| Fresh Issue | Approx ā¹29.14 Crores |
| Issue Type | Book build Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Speciality Medicines IPO Review & Key Points
- Review: Neutral
Speciality Medicines IPO Market Lot
The Speciality Medicines IPO minimum market lot is 2,000 shares with ā¹2,48,000 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 2,000 | ā¹2,48,000 |
| Retail Maximum | 2 | 2,000 | ā¹2,48,000 |
| S-HNI Minimum | 3 | 3,000 | ā¹3,72,000 |
| S-HNI Maximum | 8 | 8,000 | ā¹9,92,000 |
| B-HNI Minimum | 9 | 9,000 | ā¹11,16,000 |
IPO Reservation
| Investor Category | Share Offered | Shares (%) |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 2% |
| NII Shares Offered | – Shares | 49% |
| Retail Shares Offered | – Shares | 49% |
Speciality Medicines IPO Dates
The Speciality Medicines IPO date is March 20 and the close date is March 24. The Speciality Medicines IPO allotment will be finalized on March 25 and the IPO listing on March 30.
| IPO Open Date: | March 20, 2026 |
| IPO Close Date: | March 24, 2026 |
| Basis of Allotment: | March 25, 2026 |
| Refunds: | March 27, 2026 |
| Credit to Demat Account: | March 27, 2026 |
| IPO Listing Date: | March 30, 2026 |
| IPO Bidding Cut-off Time: | March 24, 2026 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are Parth B Goyani and Goyani Sumit Babubhai.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 64,35,796 | 59.28% |
| Promoter Holding Post Issue | 87,85,796 | -% |
Objects of the Issue & Utilisation of Proceeds
| Purpose | Crores |
| Setting up of the Research and Development (R&D) Centre | ā¹13.31 |
| Product registration in the international markets | ā¹2.89 |
| Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company | ā¹1.75 |
| To Meet Working Capital Requirements | ā¹12.00 |
| General Corporate Purpose | ā¹- |
About Speciality Medicines IPO
One of the leading companies,ā Speciality Medicinesā was founded in 2021 and started a business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases.
Moreover, the company operates in two ways: (a) contract manufacturing of finished formulations for international markets, and (b) marketing and distribution of sourced specialty pharmaceutical products.
Further, the company has around 7 registered products overseas, and 54 products are in the registration process across 5 countries.
Speciality Medicines IPO Company Financial Report
Amount ā¹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2024 | ā¹27.66 | ā¹23.10 | ā¹2.93 | ā¹22.68 |
| 2025 | ā¹58.54 | ā¹49.85 | ā¹8.61 | ā¹39.98 |
| Oct 2025 | ā¹36.93 | ā¹30.80 | ā¹6.06 | ā¹45.57 |
Speciality Medicines IPO Valuation – FY2025
Check Speciality Medicines IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 37.85% |
| ROCE: | 33.39% |
| EBITDA Margin: | 15.60% |
| PAT Margin: | 14.77% |
| Debt to equity ratio: | 0.17 |
| Earning Per Share (EPS): | ā¹14.10 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 28.42% |
| Net Asset Value (NAV): | ā¹47.07 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Remus Pharmaceuticals Limited | 65.21 | 12.25 | 15.02% | 434.25 | 620.36 Cr. |
| Trident Lifeline Limited | 10.22 | 27.59 | 18.23% | 56.05 | 86.96 Cr. |
| Mono Pharmacare Limited | 1.75 | 13.87 | 9.90% | 17.66 | 168.34 Cr. |
IPO Lead Managers aka Merchant Bankers
- Unicon Capital Services Pvt. Ltd.
Company Address
Speciality Medicines Ltd.
913, One World West, S. No. 396, FP 119,
Village- Vejalpur, Ahmadabad City,
Ahmedabad, Gujarat, India,
Ahmedabad, Gujarat, 380051
Phone: +91 22 4604 5344
Email: investors.grievances@specialitymedicine.com
Website: https://www.specialitymedicine.com/
IPO Registrar
Skyline Financial Services Pvt. Ltd.
Phone: 02228511022
Email: ipo@skylinerta.com
Website: https://www.skylinerta.com/ipo.php
Speciality Medicines IPO FAQs
What is Speciality Medicines IPO?
When Speciality Medicines IPO will open for subscription?
What is Speciality Medicines IPO Investors Portion?
How to Apply the Speciality Medicines IPO?
What is Speciality Medicines IPO Issue Size?
What is Speciality Medicines IPO Price Band?
What is Speciality Medicines IPO Lot Size?
What is the Speciality Medicines IPO Allotment Date?
What is the Speciality Medicines IPO Listing Date?
Note: The Speciality Medicines IPO price band and date are officially announced. The (Speciality Medicines IPO grey market premium) will be added to the IPO GMP page as it will start).
